P2Y12

In the field of is_associated_with::purinergic signaling, the P2Y12 is_associated_with::protein is found mainly but not exclusively on the surface of is_associated_with::blood is_associated_with::platelets, and is an important regulator in blood clotting.

P2Y12 belongs to the Gi class of a group of G protein-coupled (GPCR) is_associated_with::purinergic receptors and is a is_associated_with::chemoreceptor for is_associated_with::adenosine diphosphate (ADP). The P2Y family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various is_associated_with::adenosine and is_associated_with::uridine is_associated_with::nucleotides. This receptor is involved in platelet aggregation, and is a potential target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene.

Clinical significance
The drugs is_associated_with::clopidogrel (Plavix), is_associated_with::prasugrel (Efient, Effient) and is_associated_with::ticagrelor (Brilinta) bind to this receptor and are marketed as is_associated_with::antiplatelet agents.

P2Y12 inhibitors do not change the risk of death when given to people who have had a NSTEMI. They do however increase the risk of bleeding and decrease the risk of further cardiovascular problems. Thus their routine use is of questionable value.